Borderline resectable giant hepatic cavernous hemangioma and coexisting hemangiomatosis should be a new indication for living donor liver transplantation:A report of two cases  

作　　者：Sung-Min Kim Deok-Bog Moon Young-In Yoon Sung-Gyu Lee 

机构地区：[1]Division of Hepatobiliary Surgery and Liver Transplantation,Department of Surgery,University of Ulsan College of Medicine,Asan Medical Center,Seoul,Korea

出　　处：《Hepatobiliary & Pancreatic Diseases International》2024年第6期653-657,共5页国际肝胆胰疾病杂志（英文版）

摘　　要：To the Editor:Hemangioma is a benign liver tumor that rarely requires treatment if the patient is asymptomatic[1].However,great cavernous hemangioma(GCH)can lead to symptoms due to its mass effect and Kasabach-Merritt syndrome(KMS)[2].GCH treatment options vary;therefore,tailoring treatment to individual patients according to their condition,such as symptoms,tumor location,and liver function,is important.Occasionally,GCH is associated with hemangiomatosis,and its boundaries with normal tissue are unclear[3],leading to a lack of consensus on the initial therapeutic approach,with literature primarily comprising case reports or series[4].This study presented two cases of GCH and coexisting hemangiomatosis;the patients underwent liver resection of the main mass to relieve symptoms but ultimately required liver transplantation(LT).We aimed to describe the role of LT in these patients.

关 键 词：HEMANGIOMA CASES DONOR 

分 类 号：R735.7[医药卫生—肿瘤]